Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2004-000086-35Phase 3Completed
Phase 3, randomised, open-label trial of insulin detemir in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: HbA1c after 52 weeks of treatment. Started Jun 2004; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2004-000086-35.